Deucravacitinib Long-Term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin 2024, 8 (6), s422. https://doi.org/10.25251/skin.8.supp.422.